DUBLIN–(BUSINESS WIRE)–The “Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region – Global Forecasts to 2027” report has been added to ResearchAndMarkets.com’s offering.
The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6%
Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact.
The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years.
Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021.
Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.
The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period.
Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.
North America held dominant share in 2021.
In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.
The prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), and Endo Pharmaceuticals Inc. (Ireland).
- Rising Prevalence of Overactive Bladder Syndrome
- Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab
- Development and Use of Innovative Intravesical Therapies
- Growing R&D Investments and the Launch of Novel Therapies in the Coming Years
- Frequent Product Recalls
- Increased Side-Effects of Anticholinergic Drugs
- Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs
- Social Stigma and Lack of Awareness About OAB
- Abbvie Inc
- Ajanta Pharma
- Altherx Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Apotex Inc
- Astellas Pharma Inc
- Bayer Ag
- Endo Pharmaceuticals Inc
- Granules India Limited
- Hisamitsu Pharmaceutical Co Inc
- Hugel, Inc
- Intas Pharmaceuticals Ltd
- Johnson & Johnson Services, Inc
- Macleods Pharmaceuticals Ltd
- Pfizer Inc
- Sun Pharmaceutical Industries Ltd
- Taiho Pharmaceutical Co Ltd
- Teva Pharmaceutical Industries Ltd
- Urovant Sciences
For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.